

1 **TITLE: Longitudinal Study on Seroprevalence and Immune Response to SARS-CoV-2 in a**  
2 **Population of Food and Retail Workers Through Transformation of ELISA Datasets**

3  
4 **AUTHORS:** Abdelhadi Djaïleb<sup>1,2,3</sup> †, Megan-Faye Parker<sup>2,3,4</sup> †, Étienne Lavallée<sup>1,2,3</sup>, Matthew  
5 Stuible<sup>5</sup>, Yves Durocher<sup>2,5</sup>, Mathieu Thériault<sup>6,7</sup>, Kim Santerre<sup>6,7</sup>, Caroline Gilbert<sup>6,7</sup>, Denis  
6 Boudreau<sup>8,9</sup>, Mariana Baz<sup>6,7</sup>, Jean-Francois Masson<sup>1,10,11</sup>, Marc-André Langlois<sup>12,13</sup>, Sylvie  
7 Trottier<sup>6,7</sup>, Daniela Quaglia<sup>1,2,3,4,14</sup> and Joelle N. Pelletier<sup>1,2,3,4\*</sup>

8 <sup>1</sup>Département de Chimie, Université de Montréal, Montréal, QC, Canada ; <sup>2</sup>PROTEO, Regroupement  
9 Québécois de Recherche sur la Fonction, l'Ingénierie et les Applications des Protéines, Québec, QC, Canada ;  
10 <sup>3</sup>Centre en Chimie Verte et Catalyse, Université de Montréal, Montréal, QC, Canada; <sup>4</sup>Département de Biochimie  
11 et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada; <sup>5</sup>Mammalian Cell Expression, Human  
12 Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada; <sup>6</sup>Centre de  
13 Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC, Canada; <sup>7</sup>Département  
14 de Microbiologie-Infectiologie et d'Immunologie, Université Laval, Québec, QC, Canada; <sup>8</sup>Département de  
15 Chimie, Université Laval, Québec, QC, Canada; <sup>9</sup>Centre d'Optique, Photonique et Laser, Université Laval,  
16 Québec, QC, Canada; <sup>10</sup>Institut Courtois, Université de Montréal, QC, Canada; <sup>11</sup>Centre Québécois sur les  
17 Matériaux Fonctionnels, Regroupement québécois sur les matériaux de pointe, Centre Interdisciplinaire de  
18 Recherche sur le Cerveau et l'Apprentissage, Montréal, QC, Canada; <sup>12</sup>Department of Biochemistry,  
19 Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; <sup>13</sup>Ottawa Center  
20 for Infection, Immunity and Inflammation (CI3), Ottawa, ON, Canada; <sup>14</sup>Département de Chimie, Université du  
21 Québec à Montréal, Montréal, QC, Canada

22 † These authors contributed equally

23 \* Corresponding author information: [joelle.pelletier@umontreal.ca](mailto:joelle.pelletier@umontreal.ca)

24

## 25 **Abstract**

26           Since the onset of the global pandemic caused by the emergence and spread of SARS-CoV-  
27 2 in early 2020, numerous studies have been conducted worldwide to understand our immune  
28 response to the virus. This study investigates the humoral response elicited by vaccination and by  
29 SARS-CoV-2 infection in the poorly studied food and retail workers in the Québec City area. The  
30 1.5-year study period spans from early 2021, when vaccination became available in this region,  
31 to mid-2022, following waves of virulence due to the emergence of the first Omicron variants.  
32 Cross-correlated with data on workplace protective measures, pre-existing conditions, activities  
33 and other potentially relevant factors, this longitudinal study applies recently developed ELISA  
34 data transformation to our dataset to obtain normal distribution. This unlocked the possibility to  
35 use the ANOVA-Welsh method for statistical analysis to obtain a statistical perspective of the  
36 serological response. Our work allows the identification of factors contributing to statistically  
37 relevant differences in the humoral response of the cohort and strengthens the utility of the use  
38 of decentralized approaches to serological analysis.

39

40

41 **KEYWORDS:** SARS-CoV-2, COVID-19 vaccination, Québec City region, humoral response, food  
42 and retail workers, ELISA, serology, longitudinal study, Omicron

## 43 Introduction

44 Following the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-  
45 CoV-2) in Wuhan (China) in late 2019, the World Health Organization (WHO) declared global  
46 pandemic status on March 11<sup>th</sup> 2020 [1–3]. Over the first three years of the pandemic, over 1.3  
47 million confirmed cases and more than 19,000 deaths were documented in the province of  
48 Québec alone (current population 8.6 million) [4]. Variants of the virus have appeared and  
49 continue to appear worldwide, often triggering new waves of infection [5]. Since December 2020,  
50 a growing number of the emerging variants have been classified as “variants of concern” (VOC)  
51 by the WHO for being highly contagious, capable of evading post-infection immunity, and by  
52 causing a higher number of hospitalizations [5].

53 Higher antibody detection in infected or vaccinated individuals has been correlated with  
54 increased protection efficiency [6–12]. This made serosurveys a central tool for evaluating and  
55 predicting the protection level against viral infections within various populations deemed at risk  
56 [7]. Studies have been predominantly carried out on cohorts of healthcare workers [13–17],  
57 immunocompromised individuals having various pre-existing conditions [18–20], hospitalized  
58 COVID-19 patients [13,21–23], the elderly [24,25] and younger individuals [26–29]. Of interest,  
59 studies also reported on a higher risk of SARS-COV-2 infection in food and retail workers during  
60 the early period (prior to vaccination) [30–34]. These workers were considered at greater risk of  
61 infection due to the customer-facing nature of their occupation, which was classified as essential  
62 by the Public Health Agency of Canada, even during periods of confinement in Québec [35].

63 To investigate this population, we performed a study on a cohort of 304 food and retail  
64 workers that covered key periods of the pandemic, including the initial vaccination campaigns

65 and the emergence of the Omicron variant. Samples collected in this work were first analyzed via  
66 a centralized laboratory platform using a standardized and automated chemiluminescent ELISA  
67 assay (hereafter referred to as the “centralized assay”) at the Serology and Diagnostics Facility of  
68 the University of Ottawa, which operated in partnership with the Public Health Agency of Canada  
69 for COVID-19 serological assays [36]. This platform performed YES/NO determination of SARS-  
70 CoV-2 vaccine seroconversion and/or infection events by measuring the IgG antibodies targeting  
71 the Wuhan-Hu-1 ancestral strain spike trimeric ectodomain (hereafter referred to as the “spike  
72 protein”), the receptor binding domain (RBD) and the nucleocapsid protein [36].

73 To greatly expand the information held in the samples, we then used a semi-automated in-  
74 house colorimetric ELISA assay developed at our decentralized site at the Université de Montréal  
75 (hereafter referred to as the “in-house assay”) [37]. With this method, we performed YES/NO  
76 detection similar to those of the centralized method to validate coherence of the analyses, using  
77 the SARS-CoV-2 Wuhan-Hu-1 ancestral spike protein and nucleocapsid protein. We then  
78 broadened the study to determine the cross-reactivity of IgG directed against the spike protein  
79 of the SARS-CoV-2 Delta and Omicron VOCs, and assessed the IgM directed against the Wuhan-  
80 Hu-1 ancestral spike and nucleocapsid proteins. Importantly, integration of a recent mathematical  
81 model [38] allowed transformation of the dataset for normalization, enabling calculation of  
82 statistical differences in antigen levels between vaccinated and unvaccinated individuals and  
83 between individuals having different job categories or potential risk factors.

84 This work is part of a collective effort and stresses the importance of rapidly developing  
85 adaptable, decentralized tests for population-level immune surveillance in response to a  
86 pandemic, even before centralized testing is available [37,39]. To our knowledge, no other study

87 has reported such an extensive 18-month longitudinal investigation during the key periods  
88 preceding and following the emergence of Omicron in a cohort of highly vaccinated food and  
89 retail workers, using both centralized and customized methods to analyze two types of  
90 immunoglobulin, three types of epitope, and antigens to three VOC [40,41], [42]. This study will  
91 inform strategies and measures to be implemented in the event of a future pandemic.

92

## 93 **Materials and Methods**

### 94 **1. Cohort composition and sample collection**

95 All recruitment, data collection interviews and sample collection activities were carried out  
96 at the Centre Hospitalier Universitaire (CHU) de Québec-Université Laval and have been described  
97 in detail [39]. Briefly, the cohort included 304 food and retail workers from the Capitale Nationale  
98 (76%) and Chaudière-Appalaches (24%) administrative regions of the Canadian province of  
99 Quebec. Individuals provided written informed consent (approved by the “Comité d’éthique de  
100 la recherche du CHU de Québec-Université Laval”, registration number 2021-5744). The Canadian  
101 Immunity Task Force (CITF) questionnaire [60] was used for data collection and data collected  
102 during interviews have been reported [39]. With an average age of 41.3 years, 58 % were female  
103 and 42% were male; nearly half (49%) worked in restaurants or bars, 37% in grocery stores and  
104 14% in hardware stores. None had a history of hospitalization linked to SARS-CoV-2 [39].

105 The observation period spanned 1.5 years, from April 2021 to October 2022. A total of 121  
106 participants reported at least one positive test during the study period. Participants attended five  
107 evenly spaced visits between April 2021 and October 2022. A blood sample and information on

108 SARS-CoV-2 risk factors, symptoms, antigen or PCR test results, and vaccination status were  
109 collected at every visit. In addition, information regarding potential risk factors (i.e., demographic,  
110 socioeconomic, behavioral, clinical, and occupational) was obtained, allowing multifactorial  
111 analysis of the cohort.

112 At each visit, a 30 mL blood sample was collected in 6 mL tubes (BD Vacutainer 367815).  
113 Sera collected between June 4<sup>th</sup> and 9<sup>th</sup>, and between July 2<sup>nd</sup> and 8<sup>th</sup>, 2020, from eight individuals  
114 (aged between 20-55 years old; 7 females and 1 male) who had never tested positive for SARS-  
115 CoV-2 were pooled and used as the negative control. Sample tubes were gently inverted, held at  
116 room temperature for 15–30 min to allow clotting and spun at 1600 g for 15 min. Serum samples  
117 (1 mL aliquots) were transferred into cryovials (Sarstedt Inc., product 72.694.006), frozen in an  
118 upright position at -20°C and stored at -80°C until shipment on dry ice to the assay site, where  
119 they were maintained at -80°C until use.

## 120 **2. SARS-CoV-2 viral antigens**

121 The National Research Council of Canada (NRC) provided trimeric recombinant SARS-CoV-2  
122 spike proteins (Wuhan-Hu-1 (SmT1, lot PRO1-429), Delta (SmT1v3 (B.1.617.2)), and Omicron BA.1  
123 (SmT1(BA.1), lot PRO7911-2]), as well as the spike receptor-binding domain (319–541 RBD)  
124 produced as described previously.[61,62] The NRC also supplied the SARS-CoV-2 nucleocapsid  
125 NCAP-1.[63]

## 126 **3. In-house ELISA (Enzyme-linked Immunosorbent assays)**

127 The semi-automated in-house colorimetric ELISA was performed as described in [45] and  
128 [37] with some modifications by adapting a semi-quantitative ELISA protocol from previous work  
129 [64–66]. Briefly, 96-well immunoassay plates were coated with 100 µL of the relevant SARS-CoV-

130 2 antigen and incubated overnight at 4 °C. They were then washed and blocked with 100 µL of  
131 3% (w/v) skimmed milk powder for 1h at room temperature (RT) and then washed again. The  
132 human serum samples were inactivated by incubating them in a block heater at 56 °C for one  
133 hour and diluted as specified (1: 15,000 for anti-spike IgGs, 1: 200 for anti-nucleocapsid IgGs, and  
134 1: 100 for anti-spike and anti-nucleocapsid IgMs). Aliquots (100 µL) of the inactivated, diluted  
135 human serum samples were then added in the prepared immunoassay plates and incubated at  
136 RT for one hour. The plates were washed, and 100 µL of the appropriately diluted host-specific  
137 secondary antibody was added (1: 30,000 Goat anti-human IgG HRP Life Technologies (Invitrogen)  
138 Catalog #31413 or 1: 10,000 Goat anti-human IgM (µ-chain specific) HRP Sigma-Aldrich Catalog #  
139 A6907), covered to block out light, incubated at RT for 1h, and then washed again. 100 µL of  
140 3,3',5,5'-tetramethylbenzidine (TMB) was then added and incubated at RT for 1h, followed by the  
141 addition of 100 µL of 2 M HCl for color development. Absorbance was measured at 450 nm.

142 Quality control was performed using a calibration standard to ensure inter-day  
143 reproducibility throughout the testing period. The calibration standard consisted of pooled  
144 clinical samples from participants who were confirmed COVID-19-positive by PCR test.  
145 Independent replicates (n = 45, performed on different assay plates over several months)  
146 performed for each antigen and immunoglobulin type determined the standard signal range for  
147 each antigen. The standard was included on each ELISA plate (3 wells on each 96-well plate).  
148 When the value obtained for the standard fell outside of the acceptable range (+/- 25% of the  
149 median value), assay results for that plate were excluded. We note that the median value was  
150 determined retrospectively, in that the 45 independent replicates were performed alongside the  
151 query samples. According to that median, we then retrospectively evaluated which 96-well plates

152 should be excluded. Those assays were repeated. The COVID-19-negative control (described  
153 above) was also included on each ELISA plate.

154 Independent replicates performed for each specific antigen and immunoglobulin type (n =  
155 45, performed on different assay plates over several months) established the negative control  
156 range for each target. Positivity thresholds were established as values above the mean of negative  
157 controls for a given target plus one standard deviation. Again, positivity thresholds were  
158 determined retrospectively.

#### 159 **4. ELISA (Enzyme-linked Immunosorbent assays) at the uOttawa High Throughput** 160 **Serology and Diagnostic Facility**

161 The automated chemiluminescent ELISA, referred to as the ‘centralized assay’, was  
162 described in [36]. Briefly, automated chemiluminescent ELISAs were performed using MicroLab  
163 Star robotic liquid handlers (Hamilton, USA) and a 405 TS/LS LHC2 plate washer (Biotek  
164 Instruments; all wash steps included four washes with 100  $\mu$ L PBST). All incubations were done  
165 at room temperature with shaking at 500 rpm. Antigens (Wuhan-Hu-1 ancestral spike, 319–541  
166 RBD, and NCAP-1 nucleocapsid) were diluted in PBS and dispensed into the wells of a 384-well  
167 high-binding polystyrene Nunc plate (Thermo Fisher Scientific, #460372) at a final amount of 50  
168 ng/well. The plates were centrifuged at  $216 \times g$  for 1 min to ensure even coating, incubated  
169 overnight, rocking at 4°C, and washed. Wells were blocked with 80  $\mu$ L of 3% w/v skim milk powder  
170 dissolved in PBST for 1 h and then washed. Samples and controls were diluted as indicated to a  
171 final concentration of 1% w/v skim milk powder in PBST, and 10  $\mu$ L was added to each well from  
172 a 96-well source plate. Plates were incubated for 2 h, and wells were washed. Secondary  
173 antibodies (as in the colorimetric assay) were diluted as indicated in 1% w/v skim milk powder in



174 PBST, and 10  $\mu$ L was added to each well. After incubation for 1 h, the wells were washed, and 10  
175  $\mu$ L of ELISA Pico Chemiluminescent Substrate (Thermo Scientific; diluted 1:2 in MilliQ H<sub>2</sub>O) was  
176 dispensed into each well. After a 5 min incubation with shaking, plates were read on a Neo2 plate  
177 reader (BioTek Instruments) at 20 ms/well and a read height of 1.0 mm [36].

## 178 **5. Data transformation and statistical analysis**

179 **Standard curve of the ELISA standard.** For calibration purposes, a parent solution referred to as  
180 the “standard” and consisting of a pool of 13 COVID-19-positive samples, was created and used  
181 throughout the study. To model the relationship between absorbance and concentration, a 12-  
182 step serial dilution of the standard was prepared. As the actual antibody concentration of the  
183 standard was unknown, the most diluted sample was arbitrarily set at a concentration of 1. Each  
184 subsequent sample was assigned a relative concentration twice that of the previous sample.  
185 Consequently, the serial dilutions included relative concentrations ( $R_c$ ) of 1, 2, 4... to 2048. ELISA  
186 of the serial dilutions was performed against each relevant antigen, in quadruplicate on each of  
187 three separate plates for a total of 12 replicates of each dilution. Each serial dilution plate also  
188 contained a negative control (pool of COVID-negative samples) and a blank control (buffer only).

189 **Modeling the relationship between absorbance and concentration.** For each antigen, the mean  
190 ELISA absorbance of each dilution of the standard was then related to the dual log of its relative  
191 concentration ( $R_c$ ) to plot a nonlinear calibration curve of O.D. versus  $\log_2[R_c]$ . To describe this  
192 relationship, we used a five-parameter logistic regression model [38]:

193 *Equation 1:* 
$$\text{Log}_2[R_c] = \text{Log}_2 \left( \frac{I}{\left[ \left( \frac{T-B}{OD-B} \right)^{\frac{1}{A}} - 1 \right]^{\frac{1}{S}}} \right)$$

194 Two of the 5 model parameters (B and T) were fixed (B = median of blank controls, T =  
195 technical limit of the spectrophotometer). The three further parameters (A = curve skewness, I =  
196  $R_c$  at the inflection point, I =  $R_c$  at the inflection point if A = 1) were predicted using the R script  
197 published in [38]. The script uses the Levenberg-Marquardt algorithm and the `nlsLM` function  
198 from R's `minpack.lm` package [38].

199 **Quality control of the model for each antigen.** To confirm the robustness of this method, we  
200 reintroduced the serial dilution data (O.D.) from the ELISA for each antigen into the equation  
201 using the parameters predicted by the model (again using the code available in [38]) to compare  
202 the trend of the experimental data points to the model, confirming the accuracy of each model.

203 **Data transformation and analysis.** The experimental ELISA data were fed into their respective  
204 antigen model for transformation. The limits of these models are their asymptotes. Any data point  
205 below the bottom asymptote could not be transformed and was removed from statistical analysis.  
206 There were no data points above the top asymptote. The number of data points removed for each  
207 antigen dataset is available in **Table S1**.


208

## 209 **Results and Discussion**

### 210 **An overview of seropositivity and IgG levels in food service and retail workers** 211 **from April 2021 to October 2022**

212 Higher binding antibody titer in infected or vaccinated individuals has been correlated with  
213 increased protection efficiency [6–12], allowing the evaluation of a population's protection level  
214 and predicting the longevity of protection [7]. During the 1.5-year study period, blood samples

215 from 304 food and retail workers were collected at five visits, each spanning a period of 4 to 7  
 216 months (**Fig. 1**). In total, 1299 samples were collected. The cohort composition is summarized  
 217 under Methods, and complete details of the recruitment method and data collected by interview  
 218 have been reported [39]. The percentage of fully vaccinated participants (defined by the Canadian  
 219 government as having received at least two doses of one or a combination of approved vaccines  
 220 [43]) was already 48% by the first visit and reached 97% at visit 5 (**Table S2**). Samples collected  
 221 during the study period were analyzed with the following objectives: (i) to determine the trend  
 222 of humoral immunological response over time and in response to critical pandemic events, such  
 223 as the emergence of new variants; (ii) to identify any relevant statistical differences related to the  
 224 workers' occupations, their vaccination status, protective measures at their workplace as well as  
 225 their underlying health conditions and lifestyle.



226  
 227 **Figure 1. Overview of ELISA from all samples assayed over 18 months (n = 1290).** **A)** In-house ELISA,  
 228 reporting the mean monthly O.D.<sub>450</sub> IgG levels for the ancestral, delta and Omicron spike protein variants  
 229 and the nucleocapsid were measured (see colored legend). Positivity threshold: ancestral spike = 0.031;  
 230 delta spike = 0.033; Omicron spike = 0.040; nucleocapsid = 0.048. **B)** Centralized ELISA, reporting the mean  
 231 antibody units per mL (BAU mL<sup>-1</sup>). IgG levels for the ancestral spike protein and the nucleocapsid were  
 232 measured (see colored legend). Visits at which samples were taken are indicated in different colors under  
 233 each graph. The approximate availability of vaccine doses to the general population in the province of  
 234 Québec is indicated by arrows [47]. Note the scales on the y-axes of (**B**): left axis for ancestral spike, right  
 235 axis for nucleocapsid.

236

237 It is advisable to use the spike protein as a reference in population-based seroprevalence  
238 studies, as the humoral immune responses it elicits are strong [44] and it is the antigen used for  
239 nearly all approved COVID-19 vaccines. IgG and IgM levels specific to the spike protein  
240 ectodomain, as well as the SARS-CoV-2 nucleocapsid protein, were determined for the ancestral  
241 strain and the Delta and Omicron VOCs, using a previously established in-house ELISA [37] [45].  
242 The use of a calibration standard made up of pooled clinical samples from PCR-diagnosed COVID-  
243 positive participants ensured reproducibility. The standard was included on each ELISA plate,  
244 enabling the retrospective establishment of a standard signal range (median +/- 25%) for each  
245 antigen. Only plates where the standard signal was within this range were considered valid;  
246 invalid assays were repeated as needed. A pool of eight pre-COVID-19 serum samples was used  
247 as a negative control and was tested with each specific antigen and immunoglobulin type.

248 Our objective was first to provide a YES/NO answer to SARS-CoV-2 vaccine seroconversion  
249 or infection and then to report on statistical differences in antibody response levels between  
250 populations of workers in our cohort. Positivity thresholds (YES) were established as values above  
251 the mean of negative controls for a given target plus one standard deviation. The positivity  
252 thresholds were determined retrospectively after most samples had been tested (see Methods).  
253 The ELISA data were either used as is (YES/NO response) or further transformed into relative  
254 concentrations ( $R_c$ ) by fitting them to a logistic function obtained using a calibration curve for  
255 each antigen for statistical analysis. [38]

256 Validation of the YES/NO results obtained with the in-house ELISA was achieved by  
257 analyzing the same clinical samples at the centralized testing site, using antigens from the same

258 source. Seropositivity was determined at the centralized testing site by ELISA to IgG against both  
259 the ancestral Wuhan-Hu-1 strain spike protein ectodomain and receptor-binding domain (RBD)  
260 and against the nucleocapsid protein [24,36]. A World Health Organization (WHO) reference  
261 standard was used to calibrate the assay [36]. The scaled luminescence values were measured  
262 and converted to titer in the form of antibody units per mL [24].

263 For statistical analysis, calibration curves were obtained by serial dilution of the standard  
264 [37,38]. As the standard solution was of unknown concentration, the most diluted sample was  
265 arbitrarily set at a concentration of 1, hence the term “relative concentration”. This  
266 transformation made it possible to normalize and statistically analyze the data using Welch’s  
267 ANOVA, which is only applicable to normally distributed data, yet allows for variance inequality  
268 (see Methods) [38].

269

## 270 **Seroprevalence in the population of workers over the timeline of the study**

271 The monthly means of anti-spike (ancestral Wuhan-Hu-1 strain) and anti-nucleocapsid IgG  
272 levels obtained with the in-house ELISA (**Fig. 1A**, reported as mean O.D. values) were compared  
273 with the centralized ELISA (**Fig. 1B**, reported as mean BAU/mL). Concordant trends of  
274 seroprevalence were observed by both methods for ELISA to the ancestral variant: anti-spike IgG  
275 levels peaked around July/August 2021 during Alpha variant dominance, coincident with the 2<sup>nd</sup>  
276 mass vaccination campaign in the region, and in February to July 2022 during Omicron  
277 dominance, coincident with the 3<sup>rd</sup> mass vaccination campaigns in the region; these observations  
278 are consistent with the trends observed more broadly in the Canadian population over the same  
279 period [46]. Concordant trends with the anti-nucleocapsid IgG levels (**Fig. 1A and B**) were also

280 observed: nucleocapsid signal remained low because relatively few people were infected (**Table**  
281 **1**) until the highly infectious Omicron variant was reported in Québec on November 29<sup>th</sup>, 2021  
282 [5]. The individual ELISA results are provided in **Fig. S1** (in-house ELISA) and **Fig. S2** (centralized  
283 ELISA).

284 We further investigated seroprevalence in this population by monitoring the IgM directed  
285 against the Wuhan-Hu-1 ancestral spike and nucleocapsid using the in-house ELISA assay. The IgM  
286 ELISA signals observed using ancestral spike and nucleocapsid antigens were consistently lower  
287 than the corresponding IgG signals, as reported in prior studies (**Fig. S3**)[37,48]. The pattern of  
288 rapid production and decline of anti-SARS-CoV-2 IgM is consistent with other reports [37,48–50].  
289 This confirms the utility of reporting on IgM to monitor populational seroprevalence shortly after  
290 vaccination or infection events, while illustrating the greater overall practicality of reporting on  
291 IgG over longer observation periods.

292

### 293 **Seropositivity in the population of workers over the timeline of the study**

294 The ELISA data allowed determination of seropositivity for each individual, at each visit  
295 (**Table 1**; **Fig. S1** and **Fig. S2**). In this standard YES/NO analysis, concordant patterns of vaccine  
296 seroprevalence (anti-spike IgG, ancestral strain) was observed between the in-house and  
297 centralized ELISA methods. A strong correspondence was also observed for naturally acquired  
298 seroprevalence (anti-nucleocapsid IgG) (**Table 1**). Furthermore, the anti-nucleocapsid IgG data is  
299 fully consistent with infection data, including reports of PCR-positive test or positive self-test,  
300 where infection among this cohort was low (fewer than 5 cases per 100 person-years) during the  
301 first waves, rapidly increasing with the emergence of Omicron (peaking at 80 cases per 100

302 person-years during the fifth wave) [39]. These observations reinforce the validity of using in-  
 303 house ELISA as a reliable instrument for populational studies during the early phases of a  
 304 pandemic [37].

305  
 306 **Table 1: Comparison of vaccine and natural seroprevalence in vaccinated participants between**  
 307 **in-house and centralized ELISA.**

ELISA method	Visit 1		Visit 2		Visit 3		Visit 4		Visit 5	
	In-house	Centralized	In-house	Centralized	In-house	Centralized	In-house	Centralized	In-house	Centralized
Total samples	304	304	297	296	291	289	194	198	194	194
Vaccine Immunity <sup>1</sup>	83%	79%	72%	93%	88%	92%	93%	98%	95%	99%
Natural immunity <sup>2</sup>	22%	9%	10%	8%	38%	16%	56%	52%	42%	59%

308  
 309 <sup>1</sup> Defined by positive anti-spike signal for in-house ELISA or the combination of positive anti-spike and anti-RBD  
 310 signals for the centralized ELISA.

311 <sup>2</sup> Defined by positive anti-nucleocapsid signal for in-house ELISA and the combination of positive anti-nucleocapsid  
 312 and anti-RBD signals for the centralized ELISA.

313  
 314  
 315 The scope of the study was broadened by monitoring Delta and Omicron anti-spike IgG  
 316 levels using the in-house ELISA assay, highlighting the adaptability of this method (**Fig. 1A**). Before  
 317 December 2021, during the period where serological response resulted predominantly from  
 318 vaccination using ancestral spike antigen and before the appearance of the Omicron VOC, the IgG  
 319 ELISA response using the Delta spike antigen was indistinguishable from that using the ancestral  
 320 Wuhan-Hu-1 spike antigen. This is consistent with prior reports of effective cross-reactivity  
 321 between these strains [37,51,52]. As the study progressed, the Omicron variant became  
 322 dominant. In contrast with the Delta variant, and also consistent with a prior report, cross-

323 reactivity with the Omicron spike antigen was weaker but nonetheless consistent with immune  
324 protection even as the viral strains continued to evolve (**Fig. 1A** and **1B**) [53].

325

## 326 **Statistical correlation between vaccination and antigen levels**

327 COVID-19 vaccines were made available to the general adult population in Québec  
328 beginning in March 2021 [47], coinciding with the beginning of this study. The Astra Zeneca  
329 COVISHIELD (Vaxzevria) was rapidly followed by the Pfizer-BioNTech and Moderna Spikevax RNA-  
330 based vaccines; all vaccines initially approved for use in the Québec region were based on the  
331 ancestral spike antigen.


332 Over the course of this 1.5-year longitudinal study, vaccination status increased even as  
333 long-term participation in the study decreased: at the first visit (V1), 48% (146 of 304 the study  
334 participants) were fully vaccinated (had received at least two doses of one or a combination of  
335 the approved vaccines [43]), V3 saw 65% (188/291 participants) fully vaccinated and V5 saw 97%  
336 (188/194) fully vaccinated (**Table S2**). We note that the increase in vaccination status from 65%  
337 at V3 to 97% at V5 resulted entirely from the drop from 291 to 194 study participants.  
338 Interestingly, all who withdrew from the study between V3 and V5 were non-vaccinated. These  
339 numbers reveal that vaccination status was strongly correlated with long-term engagement in the  
340 study and caution against assigning a significance of the near-perfect vaccination status at V5 to  
341 any criterion investigated here.

342 The in-house ELISA datasets were statistically analyzed to determine correlations of  
343 antibody levels with vaccination. Specifically, ELISA reporting on IgG using the Wuhan-Hu-1  
344 ancestral spike, Omicron spike and nucleocapsid antigens were analyzed to determine the



345 correlation between vaccination events and seroconversion, and the impact of viral evolution to  
346 the Omicron VOC on cross-reactivity. We note that, following seroconversion for anti-  
347 nucleocapsid IgG in any individual, further samples from that individual were excluded to  
348 eliminate the impact of infection on the immune response.

349 We performed statistical analysis of the in-house ELISA dataset by Welch's ANOVA test. First,  
350 mathematical data curation and transformation was performed, fulfilling the requirement that  
351 datasets adopt a normal distribution; the unequal variances of the resulting dataset precluded  
352 application of ANOVA and indicated Welch's ANOVA as appropriate. Then, the relationship  
353 between ELISA absorbance and relative IgG concentration was modeled, using a COVID-19-  
354 positive standard and applying a regression model, as previously reported by others; the data fit  
355 a five-parameter logistic function, detailed in Methods [38]. Comparison of ELISA standard curves  
356 to the model for each antigen shows excellent concordance (**Fig. 2**). Having confirmed the  
357 accuracy of each model, the in-house ELISA datasets were transformed using their respective  
358 antigen model and statistically analyzed by Welch's ANOVA test.




359

360 **Figure 2. Comparison of serial dilution ELISA data with model prediction.** ELISA data for IgG were  
361 compared with model predictions for **A)** ancestral spike, **B)** nucleocapsid, **C)** delta spike and **D)** Omicron  
362 spike antigens. X-axis: dual logarithm of the relative concentration of serial dilutions (experimental data  
363 points in black, model predicted points in red). Y-axes: O.D. of serial dilutions.  
364

365 We observed clear statistical differences in anti-spike IgG levels between unvaccinated  
366 individuals and those who have received a greater number of doses, up to a maximum of four  
367 doses (**Fig. 3**). Analysis of cross-reactivity with the Omicron variant spike antigen gave similar  
368 results, although the statistical significance was generally greater. When the analysis was  
369 repeated with inclusion of samples following seroconversion for anti-nucleocapsid IgG, the trend  
370 was conserved with an increase statistical difference (**Fig. S4**). Although this may be due to the  
371 greater number of datapoints analyzed, it is more likely due to the additional immunity-provoking

372 event of the infection in the nucleocapsid-seroconverted individuals. In addition to providing an  
373 additional event of antigen exposure, vaccination and infection together have been shown to  
374 provide a greater response than either alone [54].



375  
376 **Figure 3. Comparative assessment of humoral immune response in unvaccinated and vaccinated,**  
377 **nucleocapsid-negative individuals.** ELISA assays measuring ancestral or Omicron anti-spike IgG levels were  
378 analyzed collectively (all visits together). Each grouping includes all data collected (n is given) for that  
379 number of vaccine doses (0 to 4, x-axis); ‘n’ excludes samples of individuals following determination of  
380 seropositivity for anti-nucleocapsid IgG and includes any sample taken at different visits for the same  
381 individual whose vaccination status did not change. X-axis: number of vaccine doses received (minimum 7  
382 days post-vaccination). Y-axis: data points after logarithmic transformation. The median (solid line) and  
383 quartiles (dashed lines) are shown in the violin plots; no outliers were removed. Statistical significance: \*,  
384 p < 0.05; \*\*, p < 0.01; \*\*\*\*, p < 0.0001.


385  
386  
387 It is important to note that the samples were collected without regard for the dates of  
388 vaccination of the individuals. Therefore, the observed serological response is averaged over  
389 many months post-vaccination for this population. This is seen in the modest increase (below  
390 statistical significance) in signal resulting from two doses of vaccine (‘primovaccination’)  
391 compared to non-vaccinated. Since sampling continued for months prior to the 3<sup>rd</sup> vaccination  
392 campaign, it should not be interpreted as poor serological response as it is subject to the expected  
393 waning of humoral response over time following primovaccination [55]. A marked increase in

394 median anti-spike IgG levels in samples following 3 or 4 vaccine doses was observed, consistent  
395 with other reports [56]. We note that the dataset included few participants having received a  
396 single vaccine dose, as many participants had already been vaccinated twice at their first sample  
397 collection visit.

398 Using the same mathematically transformed ELISA dataset, we monitored for any statistical  
399 differences in seroprevalence to the spike antigen as a result of the type of vaccine administered.  
400 Two vaccine doses (no matter the combination of vaccine products used) resulted in no statistical  
401 difference with the unvaccinated individuals (**Fig. 4A**). For three vaccine doses, a statistical  
402 difference between unvaccinated individuals and fully vaccinated participants was observed for  
403 the combination of three RNA-based vaccines (no matter the combination of Moderna/Pfizer-  
404 BioNTech products used); cross-reactivity with the Omicron spike antigen gave a higher statistical  
405 significance. Although the trend was maintained for the combination of Astra-Zeneca/2RNA  
406 vaccines, it was not statistically significant (**Fig. 4B**). However, upon including the nucleocapsid  
407 positive individuals in the analysis (**Fig. S5 A and B**), greater statistical differences were seen. As  
408 above, this could be due to the greater number of datapoints analyzed, and to the additional  
409 immunity-provoking event of the infection in the nucleocapsid-seroconverted individuals.

410 Our findings are consistent with the report that vaccine efficacy is roughly comparable,  
411 reaching around 90% seroconversion when the two doses administered are from an mRNA  
412 vaccine (i.e. Pfizer and Moderna), or when the first dose administered is AstraZeneca (viral vector  
413 vaccine) but followed by a second dose with an mRNA vaccine [57].

414



415  
416 **Figure 4. Comparative assessment of humoral immune response for different vaccine types.** ELISA assays  
417 measuring ancestral or Omicron anti-spike IgG levels were analyzed collectively (all visits together)  
418 following administration of **A)** 2 vaccine doses or **B)** 3 vaccine doses. Each grouping includes all data  
419 collected (n is given) for that type of vaccine; ‘n’ excludes samples of individuals following determination  
420 of seropositivity for anti-nucleocapsid IgG and includes any sample taken at different visits for the same  
421 individual whose vaccination status did not change. “RNA only”: either the Pfizer-BioNTech Comirnaty®  
422 mRNA COVID-19 vaccine, the Moderna Spikevax® mRNA COVID-19 vaccine, or a combination of both.  
423 “AZ/RNA” and “AZ/2RNA”: one dose of the AstraZeneca COVISHIELD® viral vector-based COVID-19 vaccine  
424 and one or two doses of an RNA vaccine, respectively. Individuals who had received the AstraZeneca  
425 vaccine only, or two doses of AstraZeneca and one of an RNA vaccine, were excluded as there was  
426 insufficient data to allow statistical analysis. Y-axes: data points after logarithmic transformation. The  
427 median (solid line) and quartiles (dashed lines) are shown in the violin plots; no outliers were removed.  
428 Statistical significance: \*, p < 0.05; \*\*\*, p < 0.0001.  
429

### 430 **Statistical analysis of antigen levels in relation to the workplace in an under-** 431 **reported yet highly exposed population**


432 The past years have seen a worldwide, concerted effort to understand the human  
433 immunological response to SARS-CoV-2. Our focus on the humoral immunological response of  
434 the underrepresented yet highly exposed group of food service and retail workers has yielded a  
435 comprehensive dataset spanning the 18-month period during which vaccination was deployed  
436 and the virus evolved into several VOCs. We solicited the participation of individuals working in  
437 bars, restaurants, grocery stores and hardware stores because these jobs, by their very nature,

438 require direct contact with customers and are therefore considered at greater risk than other  
439 types of work. Workers in these sectors in Québec often have below-average incomes and no  
440 health-related benefits [39]. A certain variability of risk exists in this cohort: while grocery stores  
441 and hardware stores remained open throughout the pandemic in Québec, bars and restaurants  
442 were periodically closed by health authorities. However, the use of protective equipment was  
443 better enforced in grocery and retail stores than in restaurants and bars, where clients stayed  
444 longer and removed masks to consume food and beverages [39].

445 We observed no overall statistical difference in humoral response between the different  
446 occupations according to ELISA when the data from all visits were analyzed collectively (all visits  
447 together) (**Fig. 5A and B**). However, certain trends emerged upon stratification by visit (**Fig. 5C**  
448 and **D**), specifically over the period of the two first visits, during which the cohort mostly became  
449 fully vaccinated (**Fig. 1**) but where the rate of infection-acquired immunity was low (**Table 2**). At  
450 visit 1, ancestral strain anti-spike IgG levels were statistically higher for the individuals working in  
451 restaurants than in any of the three other areas of occupation (**Fig. 5C**); at visit two, anti-spike IgG  
452 levels were statistically higher in those working in restaurants and hardware stores. Bars were  
453 closed in the region investigated for 3 of the 10 months spanning visit 1, coincident with evening  
454 curfews; this measure of health protection appears to have been successful in reducing exposure  
455 of bar workers relative to the other areas of occupation as nucleocapsids levels for this group are  
456 lower than for the others. In contrast, grocery and hardware stores were open throughout visit  
457 1; restaurants were also open, although they were restricted to limited capacity by periods.  
458 Interestingly, while restaurant and hardware store workers had the highest level of anti-

459 nucleocapsid IgG response at visit 1, bar and grocery store workers had higher levels from visit 2  
 460 on (although only statistically significant for visit 2 itself) (**Fig. 5D**).

461



462

463

464 **Figure 5. Effect of different occupations on the humoral immune response.** ELISA measuring **A**) ancestral  
 465 anti-spike or **B**) anti-nucleocapsid IgG levels analyzed collectively (all visits together), or **C**) ancestral anti-  
 466 anti-spike and **D**) anti-nucleocapsid IgG levels stratified by visit (V1 to V5) for serum samples collected during  
 467 the study period. Results are shown in logarithmic form, post-transformation. The median (solid line) and  
 468 quartiles (dashed lines) are shown in the violin plots; no outliers were removed. The number of data points  
 469 (n) per plot is shown. Statistical significance: \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.

470


471 An important and contentious subject throughout the pandemic has been whether wearing

472 a mask contributes to protection against exposure to the virus. There is some evidence in the

473 literature that masks provide useful protection [58]. We analyzed self-reported mask-wearing

474 habits at the workplace, finding no statistical difference in the level of anti-nucleocapsid IgG

475 (infection-induced immunity) for all visits, with the exception of visit 4 (**Fig. 6**). Data for visit 4  
476 were collected during the peak of the highly infectious Omicron variant (**Fig. 1**). Here, more  
477 people (65) reported not wearing masks than in previous visits (5 in visit 1, 11 in visit 2 and 21 in  
478 visit 3), and their anti-nucleocapsid IgG levels were significantly higher than those of people  
479 wearing masks during the same period. We hypothesize that the incidence of the Omicron variant  
480 and more relaxed mask-wearing habits contributed to the observed difference.  
481



482 **Figure 6. Impact of wearing a mask in the workplace on humoral immune response.** ELISA measuring **A)**  
483 ancestral anti-spike and **B)** anti-nucleocapsid IgG levels analyzed by visit (V1 to V5). Results are shown in  
484 logarithmic form, post-transformation. The median (solid line) and quartiles (dashed lines) are shown in  
485 the violin plots; no outliers were removed. The total number of data points (n) per plot is shown. Statistical  
486 significance: \*\*\*\*,  $p < 0.0001$ .  
487


488  
489 We found no significant differences for participants who used public or private transport to  
490 get to and from the workplace (**Fig. S6**) or for those who reported being in contact with infected  
491 people (**Fig. S7**).  
492

### 493 **Statistical findings unrelated to work-related activities**

494 While the main focus of this study was to analyze the effects of vaccination and exposure  
495 for this cohort, we had the opportunity to examine other factors thanks to the information



496 provided by participants during the survey at each visit, including level of education (**Fig. 7A**),  
 497 chronic illnesses (**Fig. 7B**), age (**Fig. 7C**), body mass index (BMI) (**Fig. 7D** and **Fig. S8**) and  
 498 participants' smoking habits (**Fig. 7E**).



499 **Figure 7. Impact of non-occupational activities on humoral immune response.** ELISA measuring ancestral  
 500 anti-spike or anti-nucleocapsid IgG levels are analyzed collectively (all visits together) and separated by **A)**  
 501 level of education, **B)** number of chronic illnesses, **C)** age, **D)** BMI and **E)** smoking status. Results are shown  
 502 in logarithmic form, post-transformation. The median (solid line) and quartiles (dashed lines) are shown  
 503 in the violin plots; no outliers were removed. The total number of data points (n) per plot is shown.  
 504 Statistical significance: \*, p < 0.05. In **(D)**, two data points were removed because the category (BMI < 18)  
 505 was not sufficiently populated to allow statistical analysis.

507  
508       No statistically significant differences were found for any of the factors analyzed, except a  
509 statistically higher ancestral anti-spike IgG response in non-smokers than in smokers ( $p < 0.05$ ).  
510 This difference was not observed in the case of natural immunity (anti-nucleocapsid IgG). This is  
511 consistent with prior observations that smokers generally show lower antibody titers or a more  
512 rapid decline of vaccine-induced IgG levels than non-smokers [59]. The results shown above were  
513 analyzed collectively (all visits together); no significant difference was observed when statistical  
514 analysis was stratified by visit.

515

## 516 **Discussion**

517       This 1.5-year longitudinal study of the humoral response elicited by vaccination and by  
518 SARS-CoV-2 infection in a cohort of 304 essential workers from food service and retail in the  
519 Québec City area continues to highlight the capacity for a decentralized approach to effectively  
520 monitor the humoral response to infection, particularly in specific, understudied populations [37].  
521 The impact of this study is amplified because cohort studies of highly vaccinated adults without  
522 pre-existing severe health problems who were not hospitalized for COVID-19 are scarce [40,41]  
523 and because few COVID-19 studies have reported longitudinal data from sampling of the same  
524 individuals over a long period [42].

525       We demonstrated data analysis first with the standard YES/NO determination of SARS-CoV-  
526 2 vaccine seroconversion and infection events. This confirmed high rates of seroconversion  
527 concomitant with each subsequent vaccination campaign and allowed to clearly observe  
528 seroconversion resulting from infection in this population of essential workers. We then obtained

529 key information by quantifying the extent of humoral response. This required that the flexible in-  
530 house (decentralized) colorimetric ELISA protocol be tuned to minimize overly high absorbance  
531 datapoints that cannot be interpreted. To enable robust statistical analysis using Welch's ANOVA  
532 test that requires normally distributed datasets, we applied data transformation to achieve the  
533 normal distribution; again, tuning the ELISA protocol was essential to produce unbiased  
534 transformed data.

535 In conclusion, the adaptability of the in-house colorimetric ELISA allowed rapid analytical  
536 intake of the new SARS-CoV-2 variant antigens as they became relevant to this population. By  
537 those means, we verified strong cross-reactivity between the ancestral and delta spike antigens,  
538 and slightly weaker cross-reactivity with the Omicron spike antigen. The results of ANOVA-Welsh  
539 statistical analysis are concordant with statistical differences reported for more widely studied  
540 cohorts such as healthcare workers, in the number of events of exposure to the antigen  
541 (vaccination or infection), in the effectiveness of vaccine types, and smoking. We further revealed  
542 differences related to occupational sectors over the period of the two first visits, during which the  
543 cohort mostly became fully vaccinated but where the rate of infection-acquired immunity was  
544 low. The flexibility of the decentralized analysis in rapidly integrating new iterations of the spike  
545 antigen and the ease of undertaking measurements in small laboratories at decentralized test  
546 sites will make this an essential complement to centralized testing in future epidemic or pandemic  
547 events.

548

## 549 **Acknowledgments**

550 We acknowledge Yan Watts for his help with the validation of statistical analysis and  
551 Christian Gervais for his role in providing SARS-CoV-2 antigenic proteins.

552

## 553 **Funding statement**

554 This study was funded by the Public Health Agency of Canada through the COVID-19  
555 Immunity Task Force (CITF) grant number 2021-HQ-000134 to ST, DB, CG, MB, JFM and JNP. Viral  
556 antigen production at the National Research Council of Canada (NRC) and in-kind support to MAL  
557 were supported by the NRC's Pandemic Response Challenge Program. This research was  
558 supported in part by Canada Research Chair CRC-2020-00171 to JNP and by the Sentinel North  
559 Research Chair at Université Laval (funded by the Canada First Research Excellence Fund) as well  
560 as by the Canada Research Chair CRC-2022-00103 to MB.

## References

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Bio Medica Atenei Parm.* 2020;91: 157–160. doi:10.23750/abm.v91i1.9397
2. Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. *J Infect Public Health.* 2020;13: 1601–1610. doi:10.1016/j.jiph.2020.07.011
3. Du Toit A. Outbreak of a novel coronavirus. *Nat Rev Microbiol.* 2020;18: 123. doi:10.1038/s41579-020-0332-0
4. Québec l de la statistique du. Population of Québec, July 1, 1971-2022 (in French only). In: Institut de la Statistique du Québec [Internet]. [cited 3 May 2023]. Available: <https://statistique.quebec.ca/en/produit/tableau/population-of-quebec>
5. Les variants du SRAS-CoV-2. In: INSPQ [Internet]. [cited 3 May 2023]. Available: <https://www.inspq.qc.ca/covid-19/labo/variants>
6. Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, et al. Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. *Clin Med.*
7. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine.* 2021;39: 4423–4428. doi:10.1016/j.vaccine.2021.05.063
8. Kubale J, Gleason C, Carreño JM, Srivastava K, Singh G, PARIS Study Team, et al. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. *mBio.* 2022;13: e01784-22. doi:10.1128/mbio.01784-22
9. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibodies to SARS-CoV-2 are associated with protection against reinfection. *medRxiv*; 2020. p. 2020.11.18.20234369. doi:10.1101/2020.11.18.20234369
10. Fu Y, Li Y, Guo E, He L, Liu J, Yang B, et al. Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19: A Retrospective Study. *Ann Intern Med.* 2021;174: 453–461. doi:10.7326/M20-3337
11. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. *Infectious Diseases (except HIV/AIDS)*; 2020 Jun. doi:10.1101/2020.06.07.20124636
12. Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. *Cell.* 2020;183: 1496-1507.e16. doi:10.1016/j.cell.2020.10.051
13. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *Eur J Immunol.* 2020;50: 2025–2040. doi:10.1002/eji.202048970

14. Iruretagoyena M, Vial MR, Spencer-Sandino M, Gaete P, Peters A, Delgado I, et al. Longitudinal assessment of SARS-CoV-2 IgG seroconversion among front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile. *BMC Infect Dis.* 2021;21: 478. doi:10.1186/s12879-021-06208-2
15. Rashid-Abdi M, Krifors A, Sälléber A, Eriksson J, Månsson E. Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study. *Infect Dis.* 2021;53: 169–175. doi:10.1080/23744235.2020.1849787
16. Bruni M, Cecatiello V, Diaz-Basabe A, Lattanzi G, Mileti E, Monzani S, et al. Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. *J Clin Med.* 2020;9: 3188. doi:10.3390/jcm9103188
17. Leomanni L, Collatuzzo G, Sansone E, Sala E, De Palma G, Porru S, et al. Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project. *Vaccines.* 2023;11: 1527. doi:10.3390/vaccines11101527
18. Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. *BMJ.* 2022;376: e068632. doi:10.1136/bmj-2021-068632
19. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell.* 2021;39: 1081-1090.e2. doi:10.1016/j.ccell.2021.06.002
20. Tuan JJ, Zapata H, Critch-Gilfillan T, Ryall L, Turcotte B, Mutic S, et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. *HIV Med.* 2022;23: 178–185. doi:10.1111/hiv.13188
21. Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology.* 2006;11: 49–53. doi:10.1111/j.1440-1843.2006.00783.x
22. Firnberg E, Labonte JW, Gray JJ, Ostermeier M. A comprehensive, high-resolution map of a gene's fitness landscape. *Mol Biol Evol.* 2014;31: 1581–1592. doi:10.1093/molbev/msu081
23. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. *J Clin Virol.* 2021;136: 104765. doi:10.1016/j.jcv.2021.104765
24. Vinh DC, Gouin J-P, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, et al. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. *Lancet Healthy Longev.* 2022;3: e166–e175. doi:10.1016/S2666-7568(22)00012-5
25. Cavanna L, Proietto M, Citterio C, Anselmi E, Zaffignani E, Stroppa EM, et al. COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety. *Vaccines.* 2022;10: 164. doi:10.3390/vaccines10020164

26. Ruedas-López A, Berzosa-Sánchez A, Illán-Ramos M, Callejas-Caballero I, Guillén-Martín S, Bodas-Pinedo A, et al. Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in children. *Microbiol Res.* 2022;264: 127145. doi:10.1016/j.micres.2022.127145
27. Bhatt M, Plint AC, Tang K, Malley R, Huy AP, McGahern C, et al. Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study. *CMAJ Open.* 2022;10: E357–E366. doi:10.9778/cmajo.20220026
28. Toh ZQ, Anderson J, Mazarakis N, Neeland M, Higgins RA, Rautenbacher K, et al. Comparison of Seroconversion in Children and Adults With Mild COVID-19. *JAMA Netw Open.* 2022;5: e221313. doi:10.1001/jamanetworkopen.2022.1313
29. Bag Soytaş R, Cengiz M, Islamoglu MS, Uysal BB, Ikitimur H, Yavuzer H, et al. Does the COVID-19 seroconversion in older adults resemble the young? *J Med Virol.* 2021;93: 5777–5782. doi:10.1002/jmv.27106
30. Lan F-Y, Suharlim C, Kales SN, Yang J. Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the USA. *Occup Environ Med.* 2021;78: 237–243. doi:10.1136/oemed-2020-106774
31. Stringhini S, Zaballa M-E, Pullen N, de Mestral C, Perez-Saez J, Dumont R, et al. Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. *Nat Commun.* 2021;12: 3455. doi:10.1038/s41467-021-23796-4
32. de Gier B, de Oliveira Bressane Lima P, van Gaalen RD, de Boer PT, Alblas J, Ruijten M, et al. Occupation- and age-associated risk of SARS-CoV-2 test positivity, the Netherlands, June to October 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020;25: 2001884. doi:10.2807/1560-7917.ES.2020.25.50.2001884
33. Furuse Y, Sando E, Tsuchiya N, Miyahara R, Yasuda I, Ko YK, et al. Clusters of Coronavirus Disease in Communities, Japan, January–April 2020. *Emerg Infect Dis.* 2020;26: 2176–2179. doi:10.3201/eid2609.202272
34. Pathela P, Crawley A, Weiss D, Maldin B, Cornell J, Purdin J, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020. *J Infect Dis.* 2021;224: 196–206. doi:10.1093/infdis/jiab200
35. Canada PS. Archived - Guidance on Essential Services and Functions in Canada During the COVID-19 Pandemic. 2 Apr 2020 [cited 3 May 2023]. Available: <https://www.publicsafety.gc.ca/cnt/ntnl-scr/crtcl-nfrstrctr/esf-sfe-en.aspx#>
36. Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. *Clin Transl Immunol.* 2022;11: e1380. doi:10.1002/cti2.1380
37. Djaïleb A, Lavallée É, Parker M-F, Cayer M-P, Desautels F, De Grandmont MJ, et al. Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. *Front Immunol.* 2023;13: 1052424. doi:10.3389/fimmu.2022.1052424

38. Lange TM, Rotärmel M, Müller D, Mahone GS, Kopisch-Obuch F, Keunecke H, et al. Non-linear transformation of enzyme-linked immunosorbent assay (ELISA) measurements allows usage of linear models for data analysis. *Virol J.* 2022;19: 85. doi:10.1186/s12985-022-01804-3
39. Kim Santerre, Mathieu Thériault, Nicholas Brousseau, Samuel Rochette, Joelle N. Pelletier, Caroline Gilbert, et al. Cohort Profile: Prospective Cohort to Study the COVID-19 Immune Response in Retail Workers in Québec, Canada (CISACOV). *medRxiv.* 2023; 2023.08.18.23294172. doi:10.1101/2023.08.18.23294172
40. Andrade LA, Bagno FF, Sérgio SA, Parise PL, Toledo-Teixeira DA, Fernandes AP, et al. Heterogeneity of humoral response patterns in mildly symptomatic, non-hospitalized COVID-19 patients: A one-year longitudinal study. *Exp Biol Med.* 2023; 15353702231157941. doi:10.1177/15353702231157941
41. Friedman-Klabanoff DJ, Tjaden AH, Santacatterina M, Munawar I, Sanders JW, Herrington DM, et al. Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership. *Vaccine.* 2022;40: 6133–6140. doi:10.1016/j.vaccine.2022.09.021
42. Aubry A, Demey B, François C, Duverlie G, Castelain S, Helle F, et al. Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. *J Clin Med.* 2021;10: 1815. doi:10.3390/jcm10091815
43. Canada PHA of. Demographics: COVID-19 vaccination coverage in Canada - Canada.ca. In: aem [Internet]. 15 Jan 2021 [cited 9 Aug 2023]. Available: <https://health-infobase.canada.ca/covid-19/vaccination-coverage/#a2>
44. Vilar S, Isom DG. One Year of SARS-CoV-2: How Much Has the Virus Changed? *Biology.* 2021;10: 91. doi:10.3390/biology10020091
45. Djaileb A, Hojjat Jodaylami M, Coutu J, Ricard P, Lamarre M, Rochet L, et al. Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. *The Analyst.* 2021;146: 4905–4917. doi:10.1039/D1AN00893E
46. Tanya J. Murphy, Hanna Swail, Jaspreet Jain, Maureen Anderson, Philip Awadalla, Lesley Behl, et al. The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023. *Can Med Assoc J.* 2023;195: E1030. doi:10.1503/cmaj.230249
47. Ligne du temps COVID-19 au Québec | INSPQ. In: Institut national de santé publique du Québec [Internet]. 5 Oct 2022 [cited 9 Aug 2023]. Available: <https://www.inspq.qc.ca/covid-19/donnees/ligne-du-temps>
48. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;71: 778–785. doi:10.1093/cid/ciaa310
49. Galipeau Y, Greig M, Liu G, Driedger M, Langlois M-A. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. *Front Immunol.* 2020;11: 610688. doi:10.3389/fimmu.2020.610688
50. Gasser R, Cloutier M, Prévost J, Fink C, Ducas É, Ding S, et al. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. *Cell Rep.* 2021;34: 108790. doi:10.1016/j.celrep.2021.108790



51. Chisanga M, Stuible M, Gervais C, L'Abbé D, Cass B, Bisson L, et al. SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. *Sens Diagn.* 2022;1: 851–866. doi:10.1039/D2SD00073C
52. Hojjat Jodaylami M, Djaïleb A, Ricard P, Lavallée É, Cellier-Goetghebeur S, Parker M-F, et al. Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. *Sci Rep.* 2021;11: 21601. doi:10.1038/s41598-021-00844-z
53. Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin K-M, Muñoz Sandoval D, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. *Science.* 2022;377: eabq1841. doi:10.1126/science.abq1841
54. Diseases TLI. Why hybrid immunity is so triggering. *Lancet Infect Dis.* 2022;22: 1649. doi:10.1016/S1473-3099(22)00746-0
55. Zember S, Bodulić K, Balent NC, Mikulić R, Markotić A, Đaković Rode O. Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. *Vaccines.* 2022;10: 1813. doi:10.3390/vaccines10111813
56. Brehm TT, Ullrich F, Thompson M, Küchen J, Schwinge D, Spier A, et al. Three Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 Infection Elicit Strong Humoral Immune Responses in Healthcare Workers. *Vaccines.* 2022;10: 1086. doi:10.3390/vaccines10071086
57. Efficacité de deux doses de vaccin contre la COVID-19 au Québec | INSPQ. In: Institut national de santé publique du Québec [Internet]. [cited 4 Aug 2023]. Available: <https://www.inspq.qc.ca/nouvelles/efficacite-deux-doses-vaccin-contre-covid-19-quebec>
58. Wang Y, Deng Z, Shi D. How effective is a mask in preventing COVID-19 infection? *Med Devices Sens.* 2021;4: e10163. doi:10.1002/mds3.10163
59. Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The Effect of Smoking on Humoral Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies. *Vaccines.* 2022;10: 303. doi:10.3390/vaccines10020303
60. Labonne S. Tools & Information for Researchers. In: COVID-19 Immunity Task Force [Internet]. [cited 19 Sep 2023]. Available: <https://www.covid19immunitytaskforce.ca/task-force-research-2/>
61. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. *medRxiv*; 2020. p. 2020.08.01.20166553. doi:10.1101/2020.08.01.20166553
62. Stuible M, Gervais C, Lord-Dufour S, Perret S, L'Abbé D, Schrag J, et al. Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells. *J Biotechnol.* 2021;326: 21. doi:10.1016/j.jbiotec.2020.12.005
63. Stocks BB, Thibeault M-P, L'Abbé D, Stuible M, Durocher Y, Melanson JE. Production and Characterization of a SARS-CoV-2 Nucleocapsid Protein Reference Material. *ACS Meas Sci Au.* 2022;2: 620–628. doi:10.1021/acsmearsciau.2c00050

64. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol.* 2020;57: e100. doi:10.1002/cpmc.100
65. Prévost J, Gasser R, Beaudoin-Bussièrès G, Richard J, Duerr R, Laumaea A, et al. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell Rep Med.* 2020;1: 100126. doi:10.1016/j.xcrm.2020.100126
66. Perreault J, Tremblay T, Fournier M-J, Drouin M, Beaudoin-Bussièrès G, Prévost J, et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. *Blood.* 2020;136: 2588–2591. doi:10.1182/blood.2020008367

## Supporting information captions

### Supporting Tables

**Table S1.** Number of data points removed for each antigen dataset.

**Table S2.** Percentage of fully vaccinated (at least two doses) individuals per visit.

### Supporting Figures

**Figure S1.** Seropositivity determined with in-house ELISA over 18 months.

**Figure S2.** Seropositivity determined with centralized ELISA over 18 months.

**Figure S3.** Overview of the ELISA IgM results over 18 months.

**Figure S4.** Impact of public transport use on immune response.

**Figure S5.** Impact of being in contact with a COVID-19 positive person on immune response.

**Figure S6.** Impact of BMI on immune response.

**Figure S7.** Comparative assessment of humoral immune response in unvaccinated and vaccinated individuals.

**Figure S8.** Comparative assessment of humoral immune response for different vaccine types.